Key Takeaways
- Cannabis Europa London 2026 occurs on May 26–27 at the Barbican Centre, serving as a key event for the cannabis industry in Europe.
- The conference addresses the impact of the U.S. rescheduling order on European operators and regulations, marking a significant shift in cannabis policies.
- With over 1,500 decision-makers and 70+ expert speakers, the event emphasizes actionable business strategies and policy discussions.
- The VIP experience offers unique networking and deal-making opportunities, crucial for companies targeting European markets.
- Attendance is vital for stakeholders eager to navigate Europe’s evolving cannabis landscape and capitalize on new opportunities.
In a global cannabis industry still wrestling with fragmented regulation, inconsistent access, and wildly uneven capital flows, one event continues to position itself as the meeting ground where clarity begins to emerge. Cannabis Europa London 2026, returning to the Barbican Centre on May 26–27, is not just another conference on the calendar. It is a strategic checkpoint for an industry entering what many believe is its most consequential phase in Europe.
Crucially, it’s also the first major international cannabis conference since the U.S. rescheduling order was signed. It is the room where what U.S. Schedule III reform actually means for European operators, investors, and policymakers will be debated, dissected, and decided.
This isn’t a hype fest. It’s where the people writing the rules sit across from the people trying to monetize them.
Europe Is No Longer “Emerging.” It Is Executing.
For years, Europe was framed as the “next big thing” in cannabis. That narrative is officially outdated. The continent is now actively shaping global policy, investment, and medical frameworks in real time.
Europe’s medical cannabis market is now valued at over $1.8 billion and growing fast. Germany’s rollout of a nationwide adult-use framework, continued legalization momentum in countries like the Czech Republic, and record investment into medical markets in the UK and Switzerland have shifted Europe from speculative to strategic.
Cannabis Europa London 2026 lands right in the middle of that transition. With more than 1,500 decision-makers expected—including operators, investors, and regulators from over 40 countries—the conference prioritizes action over observation. Throw in 70+ expert speakers and two full days of curated dealmaking, and you’ve got a recipe for serious cross-border business.
The Barbican Becomes the War Room
Set in London’s iconic Barbican Centre, the venue itself reflects the tone of the event. Brutalist, serious, and unapologetically business-first, it is a fitting backdrop for conversations that will influence regulatory frameworks across an entire continent. Few rooms outside North America bring this density of European operators, regulators, and capital into one place. For U.S. and Canadian companies, two days at the Barbican replaces months of cold outreach.
The UK remains one of the most paradoxical cannabis markets in the world—the largest exporter of medical cannabis globally, yet domestic access remains limited. For companies looking to enter or expand within Europe, understanding how to navigate regulatory bottlenecks in markets like the UK is the difference between scaling and stalling.
Agenda Built for Operators, Not Observers
As Schedule III reshapes the U.S. landscape—opening new research pathways, restructuring tax treatment, and unlocking institutional capital—the question for the industry on both sides of the Atlantic is no longer if the markets converge, but how.
The main stage will host two of the most consequential discussions on U.S. cannabis reform happening anywhere in 2026:
- The View from the Whitehouse: Rescheduling in the U.S. An unfiltered fireside on what rescheduling actually changes—and what it doesn’t. Featuring Saphira Galoob (US Cannabis Roundtable) and Bryan Lanza (Former Trump Transition Team), this session explores how much depends on the White House, the DEA, and the courts, and what continued uncertainty means for international investors.
- Schedule III and Beyond: What a Maturing U.S. Framework Means for Europe. Featuring David Ruskin (Kilpatrick Townsend & Stockton) and other key voices, this panel asks what federal recognition of medical value looks like from a European perspective—and what genuine regulatory convergence means for cross-border businesses.
Beyond policy, the real meat lies in the business conversations. Expect deep dives into M&A and capital flows, distribution and supply chains (especially the need for EU-GMP-grade products), and regulatory convergence.
The Rise of Data, Science, and Real Evidence
Gone are the days when anecdotal evidence could carry a room. Today’s European regulators demand clinical data, pilot program results, and measurable outcomes. Sessions focused on evidence-based policymaking and clinical trials reflect a broader shift toward legitimacy and standardization. The chaos is being replaced with structure. Slowly, but undeniably.
VIP Is Where the Real Conversations Happen
If the main conference is where ideas are shared, the VIP experience is where deals get done. Designed specifically for senior stakeholders, investors, and policymakers, this layer includes private roundtables, curated networking, and pre-scheduled meetings. For companies serious about European expansion, skipping the VIP layer is like showing up to a poker game and refusing to sit at the table.
Cannabis Europa London 2026 is built for professionals who understand that Europe’s cannabis market is no longer a question of “if,” but “how.” With Schedule III reform underway in the U.S., North American companies have a narrow window to position themselves in Europe before the next phase of consolidation.
Ready to get to work? You can grab your tickets via Eventbrite or the Cannabis Europa website. Use code SCHEDULE3BB at checkout for 20% OFF General or VIP tickets.
Frequently Asked Questions (FAQ)
The event takes place on May 26–27, 2026, at the Barbican Centre in London, UK.
It is the first major international cannabis conference since the U.S. rescheduling order (moving cannabis to Schedule III) was signed. The event will heavily focus on what this shift means for European operators, cross-border M&A, and global supply chains.
The event is tailored for decision-makers, including operators, investors, policymakers, and regulators. It’s ideal for those looking to expand into Europe, secure capital, or navigate complex international regulatory frameworks.
Yes! You can use the promo code SCHEDULE3BB at checkout to receive 20% off your General or VIP ticket purchase.
The VIP experience includes access to a separate space with its own agenda, invite-only roundtables, intelligence sessions, pre-bookable meeting booths, a dedicated host, a seated buffet lunch, and entry to the VIP networking drinks and Business of Cannabis Awards party.
